事件：公司发布公告，截至2026/2/12，#图迈腔镜手术机器人全球商业化订单突破200台，覆盖近50个国家和地 区，已完成商业化装机近130台。 关键数据&"质量"观察 图迈订单破200台，海外渗透持续提速 临床应用深度提升：已装机机构中，单中心手术量超百例的已有数十家，且覆盖泌尿外科、普外、胸外、妇科 等多科室，体现"装机后使用"在加深。 远程手术继续强化差异化：远程手术近800例、覆盖20多国、成功率保持100%；远程系统在中国、印度、巴西 等近10国获批，应用覆盖全球近一半人口区域。 装机节奏复盘 2024.12.31：图迈全球范围内累计商业化订单超过60台，累计商业化装机量已突破30台。 2025.10.08：图迈全球范围内累计商业化订单超过100台，累计商业化装机量已突破80台。 区域结构更均衡：覆盖的近50个国家和地区中，订单数超5台的达12个；印度累计订单14台、巴西超10台，西 班牙与澳大利亚等发达市场成为新增增长点。 图迈订单破200台，海外渗透持续提速 事件：公司发布公告，截至2026/2/12，#图迈腔镜手术机器人全球商业化订单突破200台，覆盖近50个国家和地 区，已完成商业化装机近 ...

业绩经营情况 经济观察网宝莱特（300246）近期主要热点集中于2025年业绩预亏公告的发布及股价的震荡走势。 股票近期走势 近期宝莱特股价震荡明显，近5个交易日累计下跌0.74%，区间振幅达15.66%。资金流向方面，2月12日 主力资金净流出303.71万元，占总成交额2.14%，但游资资金净流入505.01万元。成交活跃度较高，2月 10日单日换手率超9%，反映市场分歧加剧。技术面显示，股价当前处于布林带中轨附近，20日压力位 14.63元，支撑位12.35元，MACD指标偏弱。 以上内容基于公开资料整理，不构成投资建议。 宝莱特于2026年2月11日发布业绩预亏公告，预计2025年归母净利润亏损6000万元至8000万元，较上年 同期亏损幅度有所收窄。亏损主因包括市场竞争导致产品价格下降、原材料成本上涨拉低毛利率，以及 美元汇兑损失和可转债摊销费用影响。公司表示，通过控费增效措施，费用同比降低，但资产减值准备 计提对净利润产生一定压力。 ...

资金动向 根据香港联交所披露的文件，Duckling Fund,L.P.及关联方于2026年1月29日以每股均价7.9981港元增持 16万股H股股份，总价值约127.97万港元。增持后，Duckling Fund,L.P.的持股比例由5.99%升至6.04%。 业务进展情况 公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus已获得美国FDA对其关键性注册临床试验的 无附加条件批准。这一进展被视为公司全球化战略的重要突破，为后续在美国市场的商业化奠定基础。 以上内容基于公开资料整理，不构成投资建议。 经济观察网健世科技-B(09877.HK)近期发布2025年度收入预告，预期总收入约为人民币1.05亿至1.10亿 元，其中主营业务收入约人民币9000万至9200万元，其他收入及收益约人民币1500万至1800万元。这标 志着其首个商业化年度实现可观收入，主要得益于经导管人工主动脉瓣膜系统Ken-Valve的首年商业化 推广，以及多个结构心介入产品在海外收费临床植入的进展。 ...

Group 1 - On February 12, Jianda Zhixin's stock price fell by 1.37%, with a trading volume of 66.01 million yuan [1] - The financing data for Jianda Zhixin on the same day showed a financing purchase amount of 5.46 million yuan and a financing repayment of 10.02 million yuan, resulting in a net financing buy of -4.56 million yuan [1] - As of February 12, the total balance of margin trading for Jianda Zhixin was 92.45 million yuan, accounting for 6.39% of its circulating market value [1] Group 2 - As of December 31, Jianda Zhixin had 25,900 shareholders, a decrease of 10.35% from the previous period, while the average circulating shares per person increased by 11.55% to 1,949 shares [2] - For the period from January to September 2025, Jianda Zhixin reported an operating income of 14.861 billion yuan, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a 45.01% increase year-on-year [2]

Core Viewpoint - MicroPort Robotics-B (02252) has achieved a significant milestone with over 200 global commercial orders for its TiMAY® laparoscopic surgical robot, indicating widespread recognition of its clinical value and safety [1] Group 1: Company Performance - As of the announcement date, the company’s TiMAY® robot has completed nearly 130 installations worldwide, demonstrating strong market penetration [1] - The stock opened over 3% higher, currently trading at 26.8 HKD with a transaction volume of 2.987 million HKD, reflecting positive market sentiment [1] Group 2: Product and Market Expansion - The TiMAY® robot has received commercial application approvals in nearly 10 countries, including China, India, and Brazil, covering regions with nearly half of the global population [1] - The system has successfully completed nearly 800 remote surgeries across over 20 countries, maintaining a 100% success rate, which underscores its reliability and effectiveness in clinical settings [1]

2月12日，威高血净跌0.10%，成交额5795.79万元。两融数据显示，当日威高血净获融资买入额602.23 万元，融资偿还671.91万元，融资净买入-69.68万元。截至2月12日，威高血净融资融券余额合计1.17亿 元。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融资方面，威高血净当日融资买入602.23万元。当前融资余额1.16亿元，占流通市值的7.24%。 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41亿元，同 比增长7.92%。 分红方面，威高血净A股上市后累计派现6582.13万元。 融券方面，威高血净2月12日融券偿还700.00股，融券卖出600.00股，按当日收盘价计算，卖出金额2.45 万元；融券余量8900.00股，融券余额36.28万元。 ...

作为全球首个获准开展商业化应用的远程手术机器人系统，图迈远程手术机器人已在中国、印度、巴西 等近10个国家获得上市批准，其应用已覆盖全球近一半人口所在区域，并已率先进入常态化、规模化临 床应用阶段。截至目前，图迈已完成远程手术近800例，覆盖20多个国家，实施成功率继续保持100%。 消息面上，2月12日，微创机器人-B发布公告，截至本公告日，集团核心产品图迈®腔镜手术机器人全 球商业化订单突破200台，覆盖近50个国家和地区，已完成商业化装机近130台。图迈商业化订单和装机 规模的再次里程碑式跃升，标志着其临床价值在全球范围内获得持续、广泛的认可，是对图迈安全性、 稳定性、可靠性的系统性认证。来自不同国家、不同医疗体系、不同专科背景的外科医生，正在以真实 而审慎的临床决策，将图迈纳入日常手术实践与长期学科建设之中。 智通财经APP获悉，微创机器人-B(02252)高开逾3%，截至发稿，涨3.24%，报26.8港元，成交额298.7万 港元。 ...

Core Viewpoint - As of February 12, 2026, Yingke Medical (300677) closed at 40.08 yuan, down 2.6%, with a turnover rate of 1.46% and a trading volume of 68,000 hands, amounting to a transaction value of 274 million yuan [1] Group 1: Market Performance - On February 12, 2026, the net outflow of main funds was 25.52 million yuan, accounting for 9.31% of the total transaction value, while retail investors saw a net inflow of 31.69 million yuan, representing 11.56% of the total transaction value [1] - Over the past five days, the stock has experienced fluctuations in net fund flows, with notable outflows on February 9 and February 12, and a net inflow from retail investors on February 12 [2] Group 2: Financing and Margin Trading - On February 12, 2026, the financing buy-in was 19.75 million yuan, while the financing repayment was 28.53 million yuan, resulting in a net repayment of 8.78 million yuan [2] - The margin trading balance stood at 503 million yuan, with a short selling volume of 3,100 shares and a remaining short selling balance of 9.41 million yuan [3] Group 3: Company Financials and Industry Comparison - Yingke Medical's total market capitalization is 26.207 billion yuan, with a net asset value of 18.467 billion yuan and a net profit of 924 million yuan, ranking 8th, 4th, and 7th respectively in the medical device industry [5] - The company reported a year-on-year revenue increase of 4.6% to 7.425 billion yuan for the first three quarters of 2025, with a net profit increase of 34.47% to 924 million yuan [5] - The gross profit margin is 23.7%, which is significantly lower than the industry average of 51.01%, indicating potential areas for improvement [5]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in treating primary progressive multiple sclerosis (PPMS), marking a significant advancement in the treatment landscape [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with unmet needs in PPMS due to limited treatment options [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial for PPMS included 985 patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11][24]. - The safety profile of Fenebrutinib was comparable to Ocrelizumab, with a similar incidence of adverse events [22][24]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x [35][36]. - Specific segments like chemical pharmaceuticals and biological products have higher valuations, indicating investor confidence in these areas [35][36].

微创心通-B发布公告，股份合并将于2026年2月24日(星期二)起生效，并于上午九时正起开始买卖。股 份合并生效后及假设自公告日期直至股份合并生效日期概无发行或购回及注销额外现有股份，12.73亿 股合并股份将获发行并缴足。 香港联交所最新资料显示，2月12日，微创心通-B(02160)股东将股票由渣打银行(香港)转入高盛(亚洲)证 券，转仓市值4.24亿港元，占比8.53%。 ...